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Abstract: Pharmaceutical drug screening and research into diseases call for significant improvement
in the effectiveness of current in vitro models. Better models would reduce the likelihood of costly
failures at later drug development stages, while limiting or possibly even avoiding the use of animal
models. In this regard, promising advances have recently been made by the so-called “organ-on-chip”
(OOC) technology. By combining cell culture with microfluidics, biomedical researchers have started
to develop microengineered models of the functional units of human organs. With the capacity to
mimic physiological microenvironments and vascular perfusion, OOC devices allow the reproduction
of tissue- and organ-level functions. When considering drug testing, nephrotoxicity is a major cause
of attrition during pre-clinical, clinical, and post-approval stages. Renal toxicity accounts for 19% of
total dropouts during phase III drug evaluation—more than half the drugs abandoned because of
safety concerns. Mimicking the functional unit of the kidney, namely the nephron, is therefore a
crucial objective. Here we provide an extensive review of the studies focused on the development of
a nephron-on-chip device.
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1. Introduction
In the last 60 years, most scientific and technological contributions to drug research and
development (R&D) have brought about major advances; however, the pharmaceutical industry
has been facing increasing production costs and a decrease in efficacy of R&D process [1,2]. The
number of new drugs brought to market by the global bio-technology and pharmaceutical industries
per billion US dollars of R&D investment has declined steadily in this period [1,3]. Although scientific
and technological inputs into R&D have seen major advances, have not been reflected in drug R&D
efficiency and thus there has been no increase in the probability of a small molecule successfully
completing clinical trials [1]. These observations highlight the critical need for new testing approaches
to achieve reliable predictions of drug efficacy and safety in humans, as well as to reduce the number
of costly unsuccessful clinical trials.
Pre-clinical trials use two main tools, namely in vitro and animal models. The former consist
of conventional two-dimensional (2D) and three-dimensional (3D) cell cultures. Two-dimensional
cultures are a valuable tool in biomedical research, but they generally cannot reproduce tissue-specific
function, may alter phenotype expression [4], and still fail to predict drug activity in vivo [5–7].
Recent decades have witnessed the development of microengineered 3D tissue models that mimic
the physiological properties of native tissue samples, thus overcoming the major limitations posed by
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conventional cell-based assays for drug screening purposes. To date, cells of diverse embryonic origin
have been cultured on microporous, nanofibrous, and hydrogel scaffolds—the latter overcoming some
architectural and mechanical limitations of the first two [8]. Hydrogels are crosslinked networks with
a high water content; they can be formed by natural molecules or synthetic polymers [9], and they
induce cells to polarize and to interact with neighboring cells. They can be fabricated in customized
shapes, and they are highly permeable to cell culture medium, nutrients, and waste products generated
during the metabolic process [10].
In recent decades, organ decellularization has opened up new perspectives for tissue engineering
by providing scaffolds that allow cells not only to retain their phenotypic properties but also to mature
within the protein mesh provided. However, 3D scaffolds still have limitations. On the one hand, it is
difficult to monitor cell position and to later harvest cells for functional or biochemical analysis. On the
other hand, although 3D scaffolds provide important information about cell homeostasis (i.e., specific
topography, appropriate stiffness, among others), they continue to lack the mechanical stimuli found
in true cellular microenvironments (i.e., fluid shear stress, tension and compression).
In order to overcome these limitations, engineers have worked alongside biologists, physicists
and physicians to integrate 3D structures and microfluidics—a line of study that has given rise to the
development of the first microfluidic OOC prototypes. Microfluidics is the science and technology
of systems that process or manipulate small (10´9 to 10´18 liters) amounts of fluids using channels
with dimensions of tens to hundreds of micrometers [11]. This way, OOCs exploit small size and the
different behavior of liquids in microchannels, such as laminar flow [11].
2. Microfluidic Organs-on-Chip
Microfluidic OOCs are advanced platforms designed to mimic physiological structures and
continuous flow conditions, thus allowing the culture of cells in a friendlier microenvironment.
The word “organ” in OOC may be misleading. The idea is not to synthesize the whole organ
but to reproduce the minimal part able to exhibit tissue- and organ-level functionalities. On the other
hand, the word “chip” refers to the main fabrication technique, namely photolithographic etching,
borrowed from the electronic microchip manufacturing industry.
This technique enables the transfer of geometric micrometric patterns from a photomask to a
light-sensitive chemical photoresist on a substrate. Depending on the positive (or negative) formulation
of the resist, exposure selectively alters its polymerization, thus allowing the removal of exposed (or
unexposed) zones.
Microfluidics makes use of so-called “soft-lithography”, a technique that allows the reproduction
of patterns from silicon wafers to biocompatible “soft” elastomeric materials. This reproduction is
commonly achieved by pouring a liquid polymer (poly-dimethylsiloxane, PDMS) into a rigid mold
and allowing it to polymerize into an optically clear, rubber-like material [12].
The first simpler systems consisted of a single type of cell cultured in a single perfused chamber
with the aim to mimic the functions of a given tissue. Later on, researchers focused on reproducing
interfaces between distinct tissues to reproduce complex integrated organ-level responses [13].
In order to achieve this goal, more intricate designs were used to culture cell types in channels
interconnected by porous membranes. Complete and detailed protocols for the fabrication of functional
lung- and gut-on-chip devices have been published [14]. Following a pioneering study by Shuler
and coworkers [15], the latest advances are addressing interconnection between organs. Various
organ-type models have been combined, both embedding them in a single device [16,17] and by using
interconnected bioreactors [18,19]. Khademhosseini and colleagues recently reported on the use of
elastomeric free-form blood vessels to interconnect OOC systems [20].
These studies have paved the way toward in vitro models that mimic the function of the human
organism as a whole. Although significant technical progress is being made towards this goal, the
challenge continues to be not only the fabrication of functional lab-on-a-chip devices but also the
proper scaling of tissues in terms of size and metabolic output. Takayama and Wykswo and their
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respective colleagues recently compared traditional allometric scaling against two different approaches
based on histological section subdivision or the metabolic rate scaling ratio [21,22].
Wikswo and colleagues also pointed out the following major engineering challenges [23]: fluidic
control of milli- and micro-liter volumes; analytical chemistry in micro- and nano-liter volumes;
appropriate organ vascularization; blood surrogate development; and the modeling of coupled organs.
However, given the sheer magnitude of funding invested by larger agencies, these challenges could be
addressed in a timely manner [23]. As a potential improvement to current microfabrication techniques,
the 3D printing of scaffolds, both alone and directly with cells, has also been examined [24,25].
3. The Kidney
3.1. The Role of Kidneys in Drug R&D
The kidneys serve as a natural blood filter, removing water-soluble waste from the cardiovascular
system while reabsorbing useful substances (water, glucose, amino acids, etc.). Furthermore, they
contribute to homeostasis by regulating electrolytes and blood pressure and by maintaining an
acid–base balance, among other functions. Despite accounting for only 0.5% of body weight, the two
kidneys of a resting adult receive about the 22% (1.1 L/min, 1584 L/day) of total cardiac output [26].
Given that the kidneys play a major role in drug excretion [27], these organs take on
particular relevance for drug R&D. Furthermore, nephrotoxicity, which damages kidneys, is a
major cause of attrition during pre-clinical, clinical, and post-approval stages of pharmaceutical
drug development [28]. Even after drug approval, nephrotoxicity resulting from exposure has been
estimated to contribute to 19%–25% of all cases of Acute Kidney Injury (AKI) in critically ill patients [29].
Drugs cause roughly 20% of community- and hospital-acquired episodes of renal failure [30]. This
figure reaches about 66% among the eldest population [30], thus placing an increasingly heavy burden
on health care systems as the population ages (Figure 1) [31].
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(b) Proportion of the population aged 60 years or over: world and development regions 1950–2050.
Reproduced from United Nations, World Population Ageing; 2013 [31], with permission of United
Nations Publications.
In light of the above considerations, the kidneys take on particular relevan e in pharm cokinetics
(PK) studies. The guidelines of both the Food and Drug Administration (FDA) and he European
Medicin s Agency (E A) recomm d that a PK study should be carried out during the dev lopment
of a drug that is likely to be used in p tients with impaired renal function [32,33]. In particular, they
recommend characterizing drug PK in patients with different degrees of renal dysfunction and in the
healthy population. This approach is needed to evaluate dosage adjustment; however, even when
adjustments to recommended doses are followed, adverse reactions in patients with renal dysfunction
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are common [34]. Given this scenario, research into drug development and disease urgently need new
tools that better mimic kidney function.
3.2. The Kidney Functional Unit: The Nephron
The specific structural and functional unit of the kidney is the nephron. Each kidney is formed by
800,000 to 1,200,000 nephrons [26,35], each of them located across the cortex and the medulla.
Nephrons consist of a renal corpuscle connected to a complicated and twisted hollow tube
composed of a single cell layer and consisting of three more sections, namely the proximal tubule, the
intermediate tubule, and the distal tubule [26,35].
The renal corpuscle, also referred to as the glomerulus, is formed by glomerular capillaries and
the Bowman capsule. The glomerulus is responsible for renal ultrafiltration—an ultra-selective filtering
of blood plasma. Filtration is size-, charge- and shape- selective. This high selectivity occurs due to the
complex structure of the glomerular barrier [36], the main components of which are the glomerulus
epithelial cells, the podocytes, which have size-selective slit-shaped nanopores in their foot processes,
and the glomerular endothelium, which has a charge-selective surface. In general, all molecules larger
than 4.2 nm cannot cross the glomerular filtration barrier while those smaller than 2 nm can. Those
falling in between these values are rejected or allowed to cross the barrier depending on their charge
and shape. In particular, proteins (negatively charged) tend to be retained in the blood flow.
In contrast, the renal tubule reabsorbs water and pre-filtered useful substances toward the
circulatory system. This process is mediated both by osmotic pressure, as well as by active transport
by the tubular epithelial cells. Most reabsorption is performed in the proximal section of the tubule
(Figure 2).
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Figure 2. Renal ultrafiltration and reabsorption across the main sections of the nephron. 
Ultrafiltration from blood to ultrafiltrate takes place in the glomerulus. Reabsorption occurs across 
the tubule; in each section, reabsorption percentages of filtered amount are shown for the most 
relevant substances [26].  
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function that usually develops within 48 h [37]. AKI can be reversed in some cases, but in others it is 
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4. Kidney Disease Modeling
4.1. Major Kidney Diseases
Kidney conditions can usually be divided into two general subgroups depending on the extent
of renal functi impairment. AKI, previously called acute renal failure, i an abrupt loss of kidney
function that usually develops within 48 h [37]. AKI can be reversed in some cases, but in others it
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is fatal. Chronic Kidney Disease (CKD), also known as chronic renal disease, includes any condition
that causes reduced kidney function over a period of at least three months [38]. CKD is classified
into five stages on the basis of the severity of renal impairment, stage 5 denoting End-stage Renal
Disease (ESRD), meaning total and permanent kidney failure. Both AKI and CKD can arise from
various conditions, either related to the kidneys, other organs, or systemic diseases. With respect to
kidney-related diseases, some have attracted the attention of the research community due to lack of
therapeutic options and knowledge of the underlying mechanisms involved.
Glomerulonephritis (GN) is an inflammatory disease that compromises the glomeruli. One of the
major features of this condition is ultrafiltration and renal function impairment. Although the causes
vary (i.e., post-infectious GN, Immunoglobulin A nephropathy, anti-glomerular basement membrane
antibody disease, ANCA-associated vasculitis and lupus nephritis), GN leads mainly to structural
defects in podocytes, one of the cell types that ensures proper kidney function.
Polycystic Kidney Disease (PKD) is a group of monogenic disorders that result in renal cyst
development [39]. Its most common variant, Autosomal Dominant Polycystic Kidney Disease
(ADPKD), accounts for 10% of total ESRD diagnoses in the United States and Europe [40]. The
cysts destroy the renal tubular epithelium, culminating in fibrosis, renal architectural disorganization
and ultimately kidney failure. Thus far, the precise mechanisms leading to cyst formation and ADPKD
progression have not been fully elucidated, and ADPKD treatment is largely supportive [41].
Renal Fibrosis is a direct consequence of the kidney’s limited capacity to regenerate after injury [42].
Fibrosis involves excess accumulation of extra-cellular matrix (ECM, mainly composed of collagen)
and usually results in loss of function when normal tissue is replaced with scar tissue [43]. In spite of
considerable advances in related research in 2015, renal fibrosis calls for greater research efforts [44].
Kidney Stones are a common urological problem, affecting approximately 10% of men and 6% of
women and with an increasing prevalence over time in many developed countries [45,46]. Many
aspects underlying of renal stone formation remain unclear; therefore, a better understanding of
this intricate mechanism may pave the way to the development of a novel strategy to prevent this
disease [47].
4.2. Current Models of Kidney Disease
The gold standard through which to study kidney diseases is by using patient clinical
information [48]. While this method allows for exact reproduction of patient physiology, genetics,
and environment, it has limitations, such as uncontrollable variation in genetic and environmental
factors, availability and willingness of patients, and impossibility to perform genetic and biochemical
experimentation [48]. Animal models are commonly used instead, providing a more controllable
experimental system while maintaining the overall complexity of in vivo physiology. The main species
used in kidney research are rats, mice, dogs and pigs [49]. Transgenic models have also been used to
address genetic disorders [50] and the participation of cell lineages in physiological and pathological
mechanisms [51].
Unlike animal models, 2D cell culture provides data in easily exploitable and genetically controlled
environments. In the past, the main sources of cells, both primary and immortalized, were rats, dogs
and humans. Recent efforts have moved towards 3D cell cultures, using novel scaffolds to grow cells.
Cells or tubule pieces are most often embedded in hydrogel systems, where they form randomly
spaced and aligned structures [48]. For example, cultured primary kidney epithelial cells have been
isolated from ADPKD cysts to study the role of ouabain in the development of the disease [52]. By
culturing kidney cells from ADPKD patients in a 3D collagen type I matrix, those authors discovered
steroid hormone-induced cystic cell proliferation, a process that accelerates cyst formation.
Other studies involved the use of decellularized kidneys as 3D scaffolds. Techniques have been
developed to decellularize rat [53–55], porcine [55–57], monkey [58–60], and human kidneys [55].
Many attempts have been made to mimic the complex structure and cell interaction of the
glomerulus. Immortalized human podocytes and mesangial and glomerular endothelial cells have
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been established [61–63]; however, complete characterization of these cell lines in 2D culture has yet to
be achieved [48]. Glomerular endothelial cells and podocytes have also been co-cultured on opposite
sides of a nanofiber collagen type I/polycaprolactone scaffold [64].
Recent studies succeeded in generating kidney organoids via the directed differentiation of
human pluripotent stem cells [65–68]. Organoids are 3D organ-buds grown in vitro that show realistic
micro-anatomy. Their applications for the study of kidney physiology and pathology are promising.
Recent research has addressed the nephrotoxicity of pharmaceutical agents [65,69], as well as the
physiological growth and development of kidney-related structures [70].
4.3. Limitations of Current Models
While the models mentioned in the previous subsection address the lack of complex 3D tissue
architecture and the interactions found in 2D cultures in vitro, they continue to have important
limitations. Animal models vary significantly from humans in terms of gene expression. Moreover,
there are significant ethical and economic issues concerning their use. Hydrogel-based models have
the disadvantage of rapid degradation as a result of cellular remodeling and relatively low mechanical
integrity, thus reducing their capacity to withstand the shear forces caused by fluid flow and limiting
their utility for sustained cultivation [48]. Decellularized kidneys inherently lack the properties
required for high-throughput studies. The glomerular tri-layered model is promising, though culture is
performed in static, non-physiological conditions. With regards to organoids, the vascular environment
in vitro is still far from resembling that of an adult organ [71].
5. Microfluidics Kidney-on-Chip
The first attempts to reproduce a kidney functional unit on a microfluidic device date back to
2001, when Essig and colleagues cultured a proximal tubule from C57Bl/6 mice and from the LLC-PK1
bovine cell line under flow conditions [72]. They discovered how tubular flow affects the phenotype of
renal epithelial cells and proposed that flow-induced mechanical strains could be a determinant of
tubule-interstitial lesions during the progression of renal diseases. The device used was itself simple,
involving the assembly of two glass slides to form a parallel plate chamber (0.5 mm ˆ 20 mm ˆ 70 mm)
and application of a laminar flow of 1 and 5 mL/min.
Later on, in 2007, Baoudin and colleagues developed a PDMS device with functional living cell
microchambers interconnected by a microfluidic network that allowed continuous renal tubular cell
feeding and waste removal control [73]. The PDMS device was formed by two layers, each with a depth
of 100 µm. The first layer comprised a series of microchambers (300 µm ˆ 300 µm) and microchannels
(400 µm ˆ 150 µm), while the second provided an inlet microchannel network and a chamber to
distribute the culture medium. Those authors cultured Madin Darby Canine Kidney (MDCK) cells
at various initial concentrations (2.5~5 ˆ 105 cells¨ cm´2) and flow rates (0, 10, 25, 50 µL¨min´1).
The results revealed the greatest proliferation during dynamic culture (10 µL¨min´1). Basic chronic
toxicity was assessed by adding ammonium chloride (5 and 10 mM) to the culture media, obtaining a
considerable reduction in proliferation.
In 2008, Borenstein’s group developed a computational design of an ideal nephron-on-chip
device composed by three steps, reproducing the glomerular, tubular and Henle’s loop functions,
respectively [74]. The design used physiological dimensions for the channels in each step and computed
flowrates were also coherent with physiological values [35]. Nonetheless, the study was limited to
numerical simulations of urea reabsorption, and no further practical application of this design can be
found in the literature.
In 2010, another study addressed the effects of flow on renal cell culture [75]. The PDMS device
included a porous membrane (Ø = 0.4 µm) for first time, which was used to separate a flow and a
static compartment. The flow layer consisted of a single microfluidic channel (1 mm ˆ 1 cm ˆ 100 µm),
while the lower layer was formed by a PDMS well (2 mm ˆ 0.6 cm ˆ 1~2 mm). The membrane was
then sandwiched irreversibly between the two layers after oxygen plasma treatment (Figure 3).
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Figure 3. Fabrication and operation of a proximal tubule on a chip by Jang et al. [75]. (a) Device
assembly, sandwiching together a PDMS channel, polyester membrane, and PDMS reservoir using
plasma bonding; (b) Photograph showing the device, placed on a culture dish containing outer tubular
fluid, connected to the fluidic setup. Reproduced from [75] with permission of the Royal Society of
Chemistry. All rights reserved.
Control devices were developed using the same PDMS channel bonded to a glass substrate. Both
experimental and control devices were functionalized with fibronectin (10 µg¨mL´1 for 1 h) to improve
cell adhesion.
Primary rat inner medullary collecting duct (IMCD) cells were seeded and cultured statically in
the device for three days up to confluency; later, they were exposed to a fluid shear stress of 0.1 Pa for
5 h while provided with nutrients from the static compartment containing outer tubular fluid. The
results were compared with a control where no flow or basal/apical region was present. The authors
observed conformational cellular polarization. IMCD cells recognized their apical and basolateral
surfaces within the device. Fluid shear stress resulted in a three-fold increase in cell height and greater
resistance to oxidative stress. Furthermore, molecular transport (water and Na uptake by Aquaporin 2)
was found to be functional and responsive to hormone stimulation (Vasopressin, Aldosterone).
Another study worthy of mention, although with a different application, is Roy’s and Fissell’s
artificial kidney. Roy and Fissell designed a device to mimic renal ultrafiltration for implantable
hemodialysis purposes [76]. They used silicon nanoporous membranes with a geometrically controlled
pore size to reproduce ultrafiltration [77] and proximal tubule cells to improve reabsorption. The
device showed promising results with respect to an implantable artificial kidney [78] and has recently
been tested in dogs [79].
The first approach to develop a human proximal tubule-on-a-chip was published by Ingber’s
group in 2013 [6]. The device was a slightly modified version of [75], where the dimensions of the
lower PDMS well were modified (1.1 mm ˆ 1.1 cm ˆ 3 mm) while the microfluidic channel and the
membrane remained the same (Figure 4). Primary Human Proximal Tubule Epithelial Cells (HPTECs)
were plated on top of the membrane (2 ˆ 105 cells¨ cm2) under static conditions and cultured under a
moderate flow shear stress (0.02 Pa). Control cells were plated on similar ECM-coated porous polyester
membranes but cultured in the absence of flow in traditional Transwell inserts. After three days, the
cells subjected to physiological tubular flow showed enhanced differentiation, as revealed by increased
primary cilium formation, alkaline phosphatase activity, albumin transport, and glucose reabsorption.
Furthermore, the device was tested for drug-induced (cisplatin) toxicity response. A more specific
toxicity response was found in a “proximal tubule-on-a-chip” than in traditional culture, as cells were
healthier at the baseline. Moreover, a higher protective response was observed while co-administering
OCT-2 inhibitor, as well as a greater recover rate after acute cisplatin damage.
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Figure 4. Design of the human kidney proximal tubule-on-a-chip by Ingber’s group [6]. (a) The
microfluidic device consists of two PDMS channels, resembling the proximal tubule and interstitial
space, separated by an ECM-coated porous membrane. HPTECs are cultured on top of the membrane,
in the presence of a physiological level of apical fluid shear stress. (b) Device assembly: The upper layer,
polyester porous membrane, and lower layer are bonded together through surface plasma treatment.
Reproduced from [6] with permission of the Royal Society of Chemistry. All rights r served.
Some researchers have attempted to model specific renal pathologic conditions, like renal
fibrosis [80] and kidney stone formation [81]. These studies do not seek to reproduce the whole
organ functional unit but rather specific parts or a specific disease condition.
Moll and colleagues addressed the role of HK-2 cells in renal fibrosis. They cultured renal
cells on top of human dermal fibroblasts in order to examine how interactions between the two cell
types contribute to cisplatin-induced kidney injury. Tubular cells were found to affect fibroblast
gene expression.
Wei and colleagues studied kidney stone formation within a PDMS device with a 400-µm
cylindrical microfluidic channel (Figure 5) [81]. The device was functionalized with fibronectin
and seeded with proximal tu ule epithelial cells from the immortalized HK-2 line. After injection of
CaCl2 and Na3PO4, in sit formation of calcium phosphate tones was observed in real time using
Raman spectroscopy.
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Figure 5. Kidney stone formation, from Wei and colleagues [81]. (a) Green fluorescence protein (GFP)
expression showing typical basolateral staining in the monolayer of cells on the microchannel wall;
(b) Channel cross-section showing the distribution of key plasma membrane protein Na+/K+-ATPase.
Scale bars are 200 µm; (c) Photograph of the device with circular cross-section. Reproduced from [81]
with per ission of the Royal Society of Che istry. All rights reserved.
Another different technical approach for kidney-on-chip development used embedding
dialysis-like hollow fiber membranes inside a PDMS device [82]. The hollow fiber (outer diameter:
780 µm, inner diameter: 490 µm) was assembled together with the PDMS apical and basal chamber on
Micromachines 2016, 7, 126 9 of 16
a microscope slide (Figure 6). The membrane was sterilized with ethanol, incubated with 5 mg/mL
bovine fibrinogen and 50 U/mL bovine thrombin and seeded four times with HPTEC in order to
cover the whole membrane surface. Culture was then performed under flow condition for seven
days. Successive fluorescent immunostaining and electron microscopy revealed a confluent HPTEC
monolayer with polarized expression of proximal tubule and ion transport markers, as well as the
formation of microvilli on the apical side. Tubular reabsorption was tested as baseline and with
albumin and Na+/K+-ATPase inhibitor, and the results suggested that reabsorption is mediated by
active transport.
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Figure 6. A Fibrin-Based Tissue-Engineered Renal Proximal Tubule for Bioartificial Kidney Devices:
Development, Characterization and In Vitro Transport Study (2013). (a) Schematic and (b) image of the
“lab-on-a-chip” hollow-fiber bioreactor. (c) Set-up for perfusion studies. Reprinted from [82] under
CC-BY 3.0 with permission of Hindawi Publishing Corporation.
In 2013, a group at Huazhong University i Chin also developed a microfluidic device that was
an interface point be ween dialyz r mi iaturization and an OOC device [83]. Microfluidic titanium
layers with a ser entine channel (1 m wide, 500 µm h ight) were assembled tog ther, separated by
porous dialysis m mbranes. Various membrane mat rials (Poly thersulfone—PES, Mixed Cellulose
Ester—MCE, Regenerated Cellulose—RC) were tested. The device was modular, meaning that layers
could be added to increase the total interchange surface.
Two types of immortalized cells, namely HK-2 and HUVEC, were cultured in different layers. Cell
proliferation was tested for incubation in static and dynamic conditions (adding a 2-h dialysis after the
first 24 h of incubation). Filtration capacity was tested by measuring urea nitrogen and vitamin B12
clearance after single-pass dialysis. Sodium reabsorption was tested by irrigating both the blood and
dialysate channel with perfusion solution containing 140 mmol/L Na+.
The authors of that study reported a two-fold improvement in proliferation when cells were
exposed to flow stimulation. The best results were obtained with PES and MCE membranes. Urea
nitrogen and B12 clearance with a PES membrane reached physiological values when using a 6-layer
chip. Sodium reabsorption mediated by HK-2 cells was demonstrated by comparing physiologic
results with negative controls in which active cell transport was inhibited by addition of ouabain. The
Micromachines 2016, 7, 126 10 of 16
6-layer chip also reached physiological ammoniagenesis values, which are essential for the kidney to
maintain acid-base homeostasis in the body.
A recent study moved one step forward by performing a toxicology analysis multi-organ-on-chip
device [7]. Equipped with a standard microscope slide footprint, the device consisted of
four interconnected compartments to culture intestine, liver, skin and kidney tissues (respectively, 1,
2, 3 and 4 in Figure 7). The chambers were interconnected by a microfluidic channel for surrogate
blood flow which overlapped in the tubular region with a second microfluidic circuit that allowed
drainage of fluid excreted by renal epithelial cells. Each microfluidic circuit was actuated by a
dedicated on-chip peristaltic micropump. Intestine and liver cells were from a primary source, while
skin and kidney ones were from immortalized lines. Tubular cells showed correct polarization of
Na+/K+-ATPase. Furthermore, together with small intestine cells, they were able to maintain a stable
glucose gradient balance between the intestinal lumen, the surrogate blood circuit, and the excretory
circuit of the system.
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compartments are interconnected by a surrogate blood flow circuit (pink) and an excretory flow circuit
(yellow). Reproduced from [7] with permission of the Royal Society of Chemistry. All rights reserved.
6. Conclusions
Microfluidics has brought about significant advances in the de elopm nt of in vitro
micro-physiological systems able to reproduce in vivo organ function. These new tools pave the way
for drug development and clinical research into disease and may avoid the need for animal models
in the future wh le producing more i formation. Of ll the org ns that researchers have attempted
to reproduce, the kidney heads the field because of its critical relevance in drug development. The
kidneys are pivotal in most drug removal processes, as well as in drug safety evaluation.
The field of microfluidics has come a long way since th fir t ff t to reproduce the kidney
functional unit back in 2001, and considerable breakthroughs have been made toward a fully functional
OOC platform. However, there are still challenges and limitations to overcome.
Most studies focus exclusively on the tubular section of the nephron; however, there is a wide
range of illnesses or renal dysfunctions that are related to impaired glomerulus activity. In particularly,
the alteration of podocyte foot processes is responsible for inefficient blood ultrafiltration, leading to
proteinuria and other pathological conditions. A great challenge would be the addition of a glomerular
barrier to a nephron-on-chip, possibly using podocytes. In this regard, several issues need to be
addressed as podocytes culture is complicated [84] and requires precise shear stress control [85].
Another limitation is that only a few studies have worked with primary human cells. While
immortalized cell lines are easier to culture in vitro, they may introduce their slight phenotypic
mismatches with in vivo tissues and they are not patient-specific [86].
A general approach for developing an OOC is to identify key aspects of the geometrical,
mechanical and bio-chemical microenvironment of the tissue of interest. In this regard, little attention
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has been devoted to the geometrical aspect. For instance, in many developments, channel dimensions
are much larger than those of the physiological tubule.
A further pending improvement, which continues to be a challenge in OOC technology, is the
inclusion of sensors. Many analyses are still performed outside the device, using standard methods.
To obtain a truly efficient and cost-effective device, it would be pertinent to equip the device with
sensing capacity and thereby obtain direct data. Although studies have been published on other
organs and tissues, each one requires a specifically designed device. It would be opportune to develop
modular systems or even designs to include various readouts in function of the parameters required
by each experiment.
The paradox of achieving “perfect” models was put into perspective by Borges, highlighting
the uselessness of an empire map the size of an empire [87]. However, there is still scope to increase
the complexity of current models while conserving their utility. Nephron-on-chip technology has
experienced significant development over the last decade and promises to pave the way for novel tools
to study the effects of pharmaceutical agents and disease models in an organ of particular relevance
like the kidney.
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ECM Extra-cellular matrix
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FDA Food and Drug Administration
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